The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Hydroxyurea in Sickle Cell Disease: Our Experience in Western India
Open accessAbstract
Sickle cell disease (SCD) is common in tribal belt of Gujarat, but not addressed effectively as it should be with effective use of Hydroxyurea, supportive care and counseling. In our single centre study of 70 patients of SCD who were only on Folic acid and Blood transfusion support, were analyzed and followed up for 1 year in terms of their clinical symptoms, Blood transfusion requirement, laboratory parameters before and after Hydroxyurea therapy. We found statistically significant improvement in clinical symptoms and positive changes in laboratory parameters studied. This validates the well established role of Hydroxyurea in SCD as seen in the various international trials. Hence it is imperative that the well documented benefits of Hydroxyurea in various International studies should be translated into clinical practice. SCD should be treated like a chronic disorder needing preventive therapy in form of Hydroxyurea and counseling with regular follow up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Hydroxyurea is also used effectively in low-resource countries.
“Hydroxyurea is also used effectively in low-resource countries.73,79,80”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Pain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., et al. (2002) · Nature Medicine · doi:10.1038/nm799 · Cited by 1,097
Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia
Steinberg, M. H., Barton, F. B., Castro, O. L., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E. P., Bellevue, R., Olivieri, N. F., Eckman, J. R., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1645 · Cited by 928
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up
Steinberg, M. H., McCarthy, W. F., Castro, O., Ballas, S. K., Armstrong, F. D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21699 · Cited by 486
Hydroxyurea for the Treatment of Sickle Cell Anemia
Platt, O. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0708272 · Cited by 357
Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?
Powars, D., Weiss, J., Chan, L., & Schroeder, W. (1984) · Blood · doi:10.1182/blood.v63.4.921.921 · Cited by 314
Design of the multicenter study of hydroxyurea in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., McMahon, R. P., Barton, F. B., Waclawiw, M. A., & Eckert, S. V. (1995) · Controlled Clinical Trials · doi:10.1016/s0197-2456(95)00098-4 · Cited by 273
Hydroxyurea in the treatment of sickle-cell anemia.
Lw, H., & Kennedy, L. D. (1997) · PubMed · Cited by 251
Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease
Gladwin, M. T., Shelhamer, J. H., Ognibene, F. P., Pease‐Fye, M. E., Nichols, J. S., Link, B., Patel, D. B., Jankowski, M. A., Pannell, L. K., Schechter, A. N., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03274.x · Cited by 234
Treatment of Sickle Cell Anemia with Hydroxyurea and Erythropoietin
Goldberg, M. A., Brugnara, C., Dover, G. J., Schapira, L., Charache, S., & Bunn, H. F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008093230602 · Cited by 193
A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy
Bridges, K., Barabino, G., Brugnara, C., Cho, M., Christoph, G., Dover, G., Ewenstein, B., Golan, D., Guttmann, C., Hofrichter, J., et al. (1996) · Blood · doi:10.1182/blood.v88.12.4701.bloodjournal88124701 · Cited by 184 · cited 1×
“A detailed study showed that Hydroxyurea modifies the characteristics of red cells in patients with homozygous HbS disease to resemble those of patients with HbSC disease [16].”
BackgroundDeformability of oxygenated irreversibly sickled cells.
Clark, M. R., Mohandas, N., & Shohet, S. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109650 · Cited by 180
Steinberg, M., & Embury, S. (1986) · Blood · doi:10.1182/blood.v68.5.985.985 · Cited by 175
Participation of hemoglobins A and F in polymerization of sickle hemoglobin.
Goldberg, M. A., Husson, M. A., & Bunn, H. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40407-8 · Cited by 173
Stamatoyannopoulos, G., Wood, W., Papayannopoulou, T., & Nute, P. E. (1975) · Blood · doi:10.1182/blood.v46.5.683.683 · Cited by 99
Therapeutic Approaches to Hemoglobin Switching in Treatment of Hemoglobinopathies
Stamatoyannopoulos, J. A., & Nienhuis, A. W. (1992) · Annual Review of Medicine · doi:10.1146/annurev.me.43.020192.002433 · Cited by 78
The presentation, management and prophylaxis of sickle cell disease
Davies, S. C., & Brozović, M. (1989) · Blood Reviews · doi:10.1016/0268-960x(89)90023-4 · Cited by 62
Pain measurement in hospitalized adults with sickle cell painful episodes.
Ballas, S., & Delengowski, A. (1993) · PubMed · Cited by 40
Hydroxyurea and erythropoietin therapy in sickle cell anemia.
Goldberg, M. A., Brugnara, C., Dover, G., Schapira, L., Lacroix, L., & Bunn, H. F. (1992) · PubMed · Cited by 37
Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease
Steinberg, M. H., Voskaridou, E., Kutlar, A., Loukopoulos, D., Koshy, M., Ballas, S. K., Castro, O. L., & Barton, F. B. (2003) · American Journal of Hematology · doi:10.1002/ajh.10264 · Cited by 34
Armstrong, F. D., Pegelow, C. H., González, J. C., & Martinez, A. (1992) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/17.5.651 · Cited by 27
11 Bone marrow transplant for the haemoglobinopathies: past, present and future
Apperley, J. F. (1993) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(05)80074-5 · Cited by 18
Stamatoyannopoulos, G., Veith, R., Al-Khatti, A. A., Fritsch, E. F., Goldwasser, E., & PAPAYANNOPOULOU, T. (1987) · PubMed · Cited by 14
Flagged first, then by citations
Research works printed but not linked: 1
- Goldberg M, Brugnara C, Dover G, Schapira L, Lacroix L, Bunn H (1992) Hydroxyurea and erythropoietin therapy in sickle cell anemia. Semin Oncol 19:74–81
Cited by
Sorted by citations
Fetal hemoglobin in sickle cell anemia
Steinberg, M. H. (2020) · Blood · doi:10.1182/blood.2020007645 · Cited by 136
Sickle cell disease: Reducing the global disease burden
Mburu, J., & Odame, I. (2019) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13023 · Cited by 115
Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease
Qureshi, A., Kaya, B., Pancham, S., Keenan, R., Anderson, J., Akanni, M., Howard, J., & the British Society for Haematology (2018) · British Journal of Haematology · doi:10.1111/bjh.15235 · Cited by 90
Paper-based microchip electrophoresis for point-of-care hemoglobin testing
Hasan, M. N., Fraiwan, A., An, R., Alapan, Y., Ung, R., Akkus, A., Xu, J. Z., Rezac, A. J., Kocmich, N. J., Creary, M., et al. (2020) · The Analyst · doi:10.1039/c9an02250c · Cited by 73
Raman, V., Seshadri, T., Joice, S. V., & Srinivas, P. N. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2020-004322 · Cited by 42
Sickle cell disease in India: the journey and hope for the future
Gupta, K., Krishnamurti, L., & Jain, D. L. (2024) · Hematology · doi:10.1182/hematology.2024000678 · Cited by 24
Drown, L., Osei, M. A., Thapa, A., Boudreaux, C., Archer, N. M., Bukhman, G., & Adler, A. J. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00007-3 · Cited by 21
Darshana, T., Rees, D. C., & Premawardhena, A. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01781-w · Cited by 19
Chambers, T. M., Kahan, S., Camanda, J., Scheurer, M. E., & Airewele, G. E. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27365 · Cited by 17
A systematic review on hydroxyurea therapy for sickle cell disease in India
Pandey, A., Kaur, H., Borah, S., Khargekar, N. C., Karra, V. K., Adhikari, T., Jain, D., & Madkaikar, M. R. (2022) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_3447_21 · Cited by 11
Power‐Hays, A., TOMLINSON, G. A., Tshilolo, L. M., Santos, B., Williams, T. N., Olupot‐Olupot, P., Smart, L. R., Aygün, B., Lane, A., Stuber, S. E., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27244 · Cited by 13
Recent progress in the treatment of sickle cell disease: an up-to-date review
Acharya, B., Mishra, D. P., Barik, B., Mohapatra, R. K., & Sarangi, A. K. (2023) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-023-00373-w · Cited by 11
Sickle cell disease treatment and management in India: a systematic review of interventional studies
Sridevi, P., Sharma, Y., Sunnam, L. B., & Babu, B. V. (2022) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trac095 · Cited by 8
Samal, P., Paul, A., Bahirat, H., Bishoyi, A. K., & Epari, V. (2025) · Blood Research · doi:10.1007/s44313-025-00068-4 · Cited by 3
Power‐Hays, A., Namazzi, R., Dong, M., Kazinga, C., Kato, C., Aliwuya, S., McElhinney, K. E., Conroy, A. L., Lane, A., John, C. C., et al. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70071 · Cited by 2
The Indian experience with hydroxyurea in sickle cell disease: A 25-year systematic review
Jain, D., Sarvaiya, D., Mehta, S., Mohanasundaram, S., & Gogtay, J. A. (2025) · The Indian Journal of Medical Research · doi:10.25259/ijmr_330_2025 · Cited by 1
Hadia, R. (2024) · Asian Journal of Pharmaceutics · doi:10.22377/ajp.v18i02.5445
Battina, A., Gajbhiye, S. V., Chindhalore, C. A., Dakhale, G. N., Bhoyar, A., Dube, A., Kumbhalkar, S. D., Khushoo, V. K., & Juneja, R. (2026) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_270_26
Metadata
- Authors
- Deshpande, S. V., Bhatwadekar, S. S., Desai, P., Bhavsar, T., Patel, A., Koranne, A., Mehta, A., & Khadse, S.
- Corresponding author
- Deshpande, S. V.
- Venue
- Indian Journal of Hematology and Blood Transfusion
- Published
- 2015-05-16
- Volume
- 32
- Issue
- 2
- Pages
- 215-220
- ISSN
- 0971-4502 (ISSN-L)
- 0974-0449
- PMC
- PMC4788998
- OpenAlex
- W241561423
- Semantic Scholar
- 5ca6f6103302a574890ad17599473651c3ea4ab6
- Cited by
- 19
- References
- 25
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 2
- FWCI
- 0.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Indian Journal of Hematology and Blood Transfusion (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Keywords
- hydroxyurea, sickle cell disease, folic acid, blood transfusion, clinical symptoms, laboratory parameters, prophylaxis, patient counseling, Gujarat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
